What are the facts?
The plaintiff, an individual who developed an asbestos-related disease after years of workplace exposure to asbestos-containing insulation products, sued multiple manufacturers, including Owens-Corning Fiberglas Corporation, under theories of strict products liability for failure to warn. At trial, Owens-Corning sought to introduce evidence of the state of scientific and medical knowledge during the years of the plaintiff's exposure, contending that the specific risks alleged were not generally recognized or knowable by the prevailing scientific community at that time. The trial court, however, excluded most of this "state-of-the-art" evidence as irrelevant on the theory that strict liability for failure to warn does not depend on a manufacturer's knowledge or fault, and instructed the jury accordingly. The jury returned a plaintiff's verdict on the failure-to-warn claim. On appeal, the central question became whether, in a strict liability failure-to-warn case, the trier of fact may consider what risks were known or knowable at the time of manufacture and distribution, and whether evidence of the then-existing scientific knowledge is admissible for that purpose.
What is the legal issue?
In a strict products liability failure-to-warn action, must the plaintiff prove that the product's risk was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge at the time of manufacture and distribution, and is state-of-the-art evidence admissible to establish what was known or knowable?
What rule applies?
Yes. In California, strict liability for failure to warn attaches only if the particular risk was known or knowable at the time of manufacture and distribution, in light of the generally recognized and prevailing best scientific and medical knowledge. Plaintiffs bear the burden to prove the existence of such a known or knowable risk, the manufacturer's failure to provide adequate warnings, causation, and damages. Defendants may introduce state-of-the-art evidence to show the limits of scientific and medical knowledge at the time, not to prove reasonableness of conduct per se, but to establish the absence of a known or knowable risk. This rule accords with Restatement (Second) of Torts § 402A comment j and California strict liability precedent distinguishing informational defects from design and manufacturing defects.
What did the court hold?
The California Supreme Court held that in strict liability failure-to-warn cases, the risk must have been known or knowable at the time of manufacture and distribution. Evidence of the state of scientific and medical knowledge at the relevant time—state-of-the-art evidence—is admissible to determine whether the risk was known or knowable.
What is the reasoning?
The Court reconciled California's strict liability doctrine with the nature of informational defects. Unlike manufacturing or design defects, where the product's condition can be judged without regard to the manufacturer's knowledge, a duty to warn presupposes that the manufacturer knew or reasonably should have known of the risk. The Court drew on Restatement (Second) of Torts § 402A comment j, which conditions the duty to warn on knowledge or knowability through reasonable, developed human skill and foresight. It emphasized that requiring proof of knowability does not collapse strict liability into negligence: the inquiry remains product-focused (was an adequate warning provided for a risk that was known or knowable?) rather than conduct-focused (was the manufacturer reasonable?). Thus, the reasonableness of defendant's behavior remains irrelevant except insofar as it bears on whether a risk was generally recognized by the scientific community at the time. The Court rejected the argument that strict liability for failure to warn should be absolute regardless of knowability, reasoning that imposing liability for unknowable risks would be both unsound policy and inconsistent with precedent. It noted that California cases had already recognized limits on strict liability (e.g., prescription drug cases and design defect balancing) and that knowledge or knowability is inherent in the warning function. On evidentiary questions, the Court held that state-of-the-art evidence is admissible because it directly informs whether a risk was knowable; excluding such evidence would preclude the jury from assessing a necessary element. At the same time, the Court cautioned that the evidence is not a license to relitigate the reasonableness of corporate conduct, but is limited to what the generally recognized and prevailing scientific knowledge was at the time. Concluding that the trial court's exclusion of such evidence improperly prevented the jury from deciding a material element of the claim, the Court approved admission of state-of-the-art evidence and required conformity with the knowability standard.
Why is this case significant?
Anderson crystallizes a core principle of modern products liability: in failure-to-warn cases, strict liability is not absolute and turns on the state of knowledge at the time of manufacture and distribution. It gives plaintiffs and defendants clear burdens—plaintiffs must show the risk was known or knowable; defendants may counter with state-of-the-art evidence. The case guides jury instructions, motions in limine, and expert proof in toxic torts and other warning cases. For law students, Anderson is essential for understanding how California harmonizes strict liability with practical and evidentiary constraints, distinguishes failure-to-warn from design/manufacturing defects, and aligns with Restatement comment j. Its reasoning reverberates through later California cases addressing pharmaceuticals and complex product risks.
Does Anderson make strict liability the same as negligence in failure-to-warn cases?
No. Anderson preserves the distinction. Negligence focuses on the reasonableness of the manufacturer's conduct; strict liability asks whether the product was defective because it lacked an adequate warning for a risk that was known or knowable at the time. Knowability is an element defining the existence of a duty to warn, not a measure of whether the manufacturer acted reasonably. Thus, while both doctrines may consider scientific knowledge, strict liability remains product-focused.
What is "state-of-the-art" evidence and why is it admissible under Anderson?
State-of-the-art evidence describes the generally recognized and prevailing scientific and medical knowledge at the relevant time. Under Anderson, it is admissible to show whether a risk was known or knowable. The evidence is not offered to justify the defendant's conduct or show reasonableness but to establish the scope of then-existing knowledge bearing on the duty to warn. Courts may limit such evidence to prevent it from morphing into a negligence defense.
Who bears the burden of proving that a risk was known or knowable?
The plaintiff bears the initial burden to prove that, at the time of manufacture and distribution, the product posed a risk that was known or knowable in light of the prevailing scientific and medical knowledge. Once the plaintiff makes that showing, the defendant may rebut with state-of-the-art evidence suggesting the risk was not then generally recognized or discoverable using then-available scientific insights.
How does Anderson interact with design defect cases like Barker v. Lull Engineering?
Anderson addresses failure-to-warn, not design defects. In design defect cases, liability can attach under consumer expectations or risk-benefit tests without regard to the manufacturer's knowledge. By contrast, for informational defects, Anderson makes knowledge or knowability a prerequisite to a duty to warn. Thus, the analytical frameworks differ: design defects do not require proof of knowability, but failure-to-warn claims do.
Does Anderson affect prescription drug and medical device warning cases?
Yes, conceptually. California cases addressing drug and device warnings have integrated knowability principles, and later decisions (e.g., Carlin v. Superior Court) explicitly applied Anderson's framework in the pharmaceutical context. While additional doctrines (like the learned intermediary rule and federal preemption) may apply in drug/device cases, Anderson's knowability requirement remains foundational.
What jury instruction implications flow from Anderson?
Jury instructions in California failure-to-warn cases must inform jurors that plaintiffs must prove the risk was known or knowable at the time, that the warning was inadequate in light of that knowledge, and that the failure to warn was a substantial factor in causing harm. Courts should also instruct that state-of-the-art evidence is relevant only to the knowability element, not to the overall reasonableness of the manufacturer's conduct.